Search Results (151)

Background: Dengue fever is one of the most common mosquito-borne viral infections, with severe cases characterized by plasma leakage, hemorrhage, and multi-organ involvement. Identification of dengue serotypes and reliable biomarkers is essential for predicting disease progression and guiding timely interventions. Methods: This prospective cohort study was conducted at a super-speciality tertiary care hospital in southern India from July 2024 to July 2025. A total of 69 patients presenting with dengue warning signs were included in the study. Patients were categorized into the severe dengue group (n = 25) and non severe dengue group (n = 44). Clinical data, laboratory findings, dengue serotype, and serial serum samples collected on Days 1, 4, and 8 were analyzed to evaluate the predictive and monitoring efficacy of Interleukin-6 (IL-6) and Interleukin-8 (IL-8), and followed up till discharge. Results: Out of 69 dengue patients with warning signs, 32 dengue-positive patients were serotyped, which included DEN V-1 (31.3%), DEN V-2 (31.3%), DEN V-3 (15.6%), DEN V-4 (18.8%), and mixed DEN V-(2 + 3) (3.1%). Severe dengue patients exhibited a higher frequency of secondary dengue infection (IgG) than primary dengue infection (88% vs. 12%), with statistically significantly higher packed cell volume, hemoglobin levels, high AST levels, and prolonged activated partial thromboplastin time, as well as lower platelet counts and albumin levels. Platelet transfusion was given to 35 dengue patients, which had also resulted in significant length of stay in hospital in comparison to non-transfused patients. IL-6 and IL-8 levels were significantly elevated in severe dengue patients when compared to non-severe dengue patients on Day 1 and Day 4, followed by a decline on Day 8, corresponding with clinical recovery. However, the elevated IL-8 levels were observed to be significantly associated with longer hospital stays, indicating its potential role as an early predictor of disease progression. Conclusions: The observed co-circulation of multiple serotypes reflects the hyper-endemic pattern reported across India. Early measurement of these cytokines IL-6 and IL-8 helps distinguish severe from non-severe dengue among patients presenting with warning signs. IL-6 and IL-8 may have potential as biomarkers for disease severity. However their role in guiding platelet transfusion requires further investigation in non-severe cases and prioritizing timely management for those at higher risk of severe disease. Full article

Objectives: This randomized, blinded, positive-controlled phase III clinical trial aims to evaluate the safety and immunogenicity of the Sabin strain-based inactivated polio vaccine (sIPV) produced by Biominhai in healthy infants after primary and booster immunization. Methods: A total of 1200 healthy infants, aged 2 months, were randomly assigned to two groups in a 1:1 ratio to receive either one dose of sIPV or the control wIPV at 2, 3, and 4 months of age, followed by a booster dose at 18 months. The safety and immunogenicity of both the primary and the booster immunization were assessed. Results: The incidence of adverse reactions (AEs) was significantly lower in the sIPV group compared to the wIPV group after the primary immunization. Specifically, redness was the most frequently reported AE, occurring in 9% of the sIPV group versus 14% in wIPV (p = 0.01). Diarrhea was also less common in the sIPV group (3%) compared to the wIPV group (8%, p = 0.0004). Moreover, there were no significant differences in incidence, severity, or symptoms of AEs between the groups after the booster immunization. Most AEs were classified as grade 1, and notably, no serious AEs (SAEs) were associated with the trial vaccine. Seroconversion rates for types 1, 2, and 3 poliovirus neutralizing antibodies, in the sIPV group, exceeded 98% at 30 days after primary immunization and remained above 90% at 30 days after booster immunization. Notably, seroconversion rates for all three serotypes following both primary and booster immunizations were non-inferior to those observed in the wIPV group. Additionally, the geometric mean titers (GMTs) of neutralizing antibodies against all types were significantly higher in the sIPV group. Conclusions: The sIPV produced by Biominhai demonstrated comparable safety and immunogenicity to the control vaccine after both primary and booster immunizations. Full article

Background: Public catering is an underexplored One Health interface where structurally complex food-transport equipment may sustain reservoirs of antimicrobial-resistant bacteria. We investigated Escherichia coli from reusable institutional catering food-transport containers, focusing on a difficult-to-clean pressure-relief/ventilation valve compartment. Our objectives were to quantify phenotypic resistance using applied clinical breakpoints, assess inhibitor-synergy outcomes in ESBL confirmatory testing, and contextualize inhibitor-positive isolates by whole-genome sequencing (WGS). Methods: E. coli was isolated from containers sourced from 17 institutions and three central kitchens using ISO 16649-2. Minimum inhibitory concentrations (MICs) were determined by broth microdilution. Extended-spectrum β-lactamase (ESBL) confirmatory testing used cefotaxime/ceftazidime ± clavulanate; inhibitor positivity was defined as a ≥3 two-fold MIC decrease in the presence of clavulanate in isolates meeting CLSI screening thresholds. Inhibitor-positive isolates underwent WGS and CARD-based resistome profiling. Results: Resistance was most frequent to colistin (10, 10.8%), followed by doxycycline (8, 8.6%), florfenicol (7, 7.5%), enrofloxacin (4, 4.3%), and gentamicin (3, 3.2%). Third-generation cephalosporin resistance by clinical breakpoints was uncommon (cefotaxime: 2, 2.2%; ceftazidime: 1, 1.1%). Inhibitor-positive ESBL confirmatory phenotypes occurred in 30 isolates (32.3%), which were sequenced. WGS identified 45 resistance-associated genes across inhibitor-positive isolates but detected no classical ESBL genes; all carried chromosomal ampC/ampH alongside ubiquitous efflux-associated determinants. All WGS isolates belonged to phylogroup A, with serotype O154:H9 (20, 66.7%) and ST5549 (17, 56.7%) predominating. Conclusions: Institutional catering food-transport containers can harbor AMR E. coli, with colistin as the most frequent resistance phenotype and frequent inhibitor-positive ESBL confirmatory profiles that, in this set, were not explained by classical ESBL gene carriage. Integrating phenotype, WGS resistomics, and lineage structure supports targeted hygiene surveillance and risk-informed One Health monitoring in mass catering systems. Full article

Diagnostic testing of foot-and-mouth disease virus (FMDV) currently utilizes reverse transcription quantitative PCR (RT-qPCR) to detect the presence of viral RNA and double antibody sandwich ELISAs (DAS-ELISAs) to determine viral serotype. Serotype identification is critical to support informed vaccine selection to combat outbreaks. While DAS-ELISAs are capable of serotype identification, the test suffers from low sensitivity and requires a viral isolate for successful detection. In this study, we developed FMDV-ONTAPS: an Oxford Nanopore Technologies Amplicon P1 Sequencing protocol involving reverse transcription-PCR to amplify P1 of the FMDV genome, and Nanopore sequencing of the amplicons to provide genetic data for serotype and subtype/topotype identification. FMDV isolates representing all seven serotypes were successfully sequenced with this method. Additionally, the protocol successfully provided serotype identification from a variety of specimen matrices obtained from experimentally infected animals that included milk, serum, oral and nasal swabs, tissue suspensions, vesicular fluid, and oral fluid. The limit of detection for FMDV cell culture isolates was comparable for both sequencing and RT-qPCR detection. RT-qPCR Cq values for clinical samples evaluated ranged from 8 to 28.21. Sequencing was successful for all samples except for a single tissue suspension sample (Cq of 28.21). Identification of FMDV serotype in clinical samples is critical for effective outbreak response, and Nanopore sequencing offers a timelier and more sensitive alternative to DAS-ELISAs. Full article

Background: Although pneumococcal conjugate vaccines (PCVs) have substantially reduced invasive pneumococcal disease, the emergence of non-vaccine serotypes and antimicrobial-resistant strains has driven the development of higher-valency vaccines. To support functional immune evaluation of these vaccines, we developed and validated a sixplexed opsonophagocytic killing assay (OPA) covering 24 pneumococcal serotypes. Methods: Eight additional serotypes, beyond the 16 included in the conventional fourplex OPA, were generated through stepwise natural mutation under increasing concentrations of ciprofloxacin or doxycycline. Assay conditions were optimized by evaluating multiple effector-to-target (E:T) ratios and baby rabbit complement (BRC) concentrations to minimize non-specific killing (NSK). Validation assessed (1) specificity using inhibition OPA with homologous and heterologous polysaccharides, (2) accuracy by comparison with the single-serotype OPA (SOPA), and (3) precision across five independent experiments using the coefficient of variation (CV). Results: An E:T ratio of 200:1 combined with 10% BRC consistently maintained NSK below 30% across all assay sets. High serotype specificity was demonstrated by near-complete inhibition following homologous polysaccharide adsorption for all serotypes except serotypes 4 and 8, which exhibited very low opsonic indices. Results from the sixplexed OPA showed strong concordance with SOPA, and overall assay precision was acceptable, with CVs generally below 30% when serotypes with very low opsonic activity were excluded. Conclusions: The sixplexed OPA expands functional antibody assessment from 16 to 24 serotypes within four assay sets, providing an efficient and scalable platform for immunogenicity evaluation of current and next-generation high-valency pneumococcal vaccines. Full article

The prevalence of metabolic dysfunction-associated steatohepatitis (MASH) is rising worldwide. hFGF1^ΔHBS, a variant of human fibroblast growth factor 1 with three substitutions in its heparin-binding sites, was previously shown by our group to ameliorate fatty liver. However, hFGF1^ΔHBS also significantly modulates systemic metabolism, making it unclear whether its hepatic benefits arise from direct liver-specific actions. Additionally, its poor pharmacokinetic profile underscores the need for alternative delivery strategies. Here, we employed adeno-associated virus serotype 8 under the thyroxine-binding globulin promoter (AAV8-TBG) to achieve sustained, hepatocyte-specific expression of hFGF1^ΔHBS. In high-fat-, high-cholesterol-diet-fed apolipoprotein E knockout mice, liver-directed hFGF1^ΔHBS expression markedly reduced hepatic steatosis, inflammation, and fibrosis, independent of changes in body weight, blood glucose, insulin sensitivity, body composition, or circulating triglyceride and cholesterol levels. Mechanistically, hFGF1^ΔHBS gene transfer normalized fatty acid synthesis and suppressed fatty acid uptake by downregulation of stearoyl-CoA desaturase-1 and cluster of differentiation 36. Importantly, these therapeutic effects were achieved without inducing hepatic hyperproliferation, as evidenced by unchanged expression of proliferating cell nuclear antigen and antigen Kiel 67. Collectively, our findings demonstrate that hFGF1^ΔHBS exerts direct hepatoprotective effects and that AAV8-TBG-mediated liver-directed hFGF1^ΔHBS delivery represents a safe and effective strategy for treating MASH. Full article

Fowl adenoviruses are opportunistic emerging viruses that spread widely in fowls, infecting birds of all ages, including young broiler chicks. This study aims to genotype the current adenovirus strains associated with inclusion body hepatitis hydropericardium syndrome (IBH-HPS) among infected broilers in Upper Egypt and to evaluate their pathogenic features. In 2024, 100 tissue samples were collected across Assiut and Sohag governorates in Upper Egypt for genetic characterization and pathogenicity evaluation. FAdVs were detected in 22% (11/50) of flocks. Typical FAdV lesions of dead embryos were observed after seven days post egg inoculation. Regarding the PCR assay of the hexon gene, only 8 of 30 samples were confirmed positive at 897 bp, yielding a 26.6% positivity rate. The remaining samples were considered negative using established RT-qPCR protocols for other viral pathogens. Partial sequencing of the hexon gene revealed that FAdV isolates (n = 4) clustered within FAdV species-D serotype 2/11, as determined by phylogenetic analysis. The four isolates shared (98–99%) and (94–100%) nucleotide and amino-acid similarities to FAdV-D of Israeli strains (2019–2020) and contemporary Egyptian isolates (2022), respectively, and low genetic divergence (54–81%) in comparison with other documented species. The amino acid sequence alignment and 3D structure indicate that the four immunogenic HVRs are located in the L1 region of the hexon protein, and that the highly conserved ⁹¹GQMTT⁹⁵, a specific region for FAdV-D serotype 2/11, is present. Regarding pathogenicity, the gross and histopathological findings observed clearly demonstrate the systemic pathogenicity of FAdV-2/11 in the infected group, with a final mortality rate of 30% at seven days post-infection (dpi). The FAdV DNA in hepatic tissues and cloacal swabs was confirmed by the PCR method at 3 dpi and 5 dpi. These results emphasize the circulating of FAdV-2/11 species D in Upper Egypt and highlight the significant need for a single inactivated vaccine that effectively targets the relevant FAdV serotypes to achieve broader and more efficient protection. Full article

Bluetongue (BT) is a noncontagious, arthropod-borne viral disease of domestic and wild ruminants caused by bluetongue virus (BTV), an arbovirus of the Orbivirus genus within the Sedoreoviridae family. At least 36 serotypes have been identified globally; recurrent circulation of BTV-1, -4, and -8, along with the recent emergence of BTV-3 in northern Europe, underscores a persistent incursion risk for Mediterranean herds. Key drivers include climate-driven expansion of Culicoides vector niches, windborne dispersal, animal movements, and subclinical reservoirs in cattle and goats. As no specific treatment is currently available, control of bluetongue disease still relies largely on vaccination. Live-attenuated vaccines and inactivated vaccines have reduced incidence, but important limitations persist: risk of reversion and the possibility of reassortment for LAVs; requirement for multiple doses and limited cross-protection for inactivated products; and the absence of DIVA capability for both. As an alternative, next-generation platforms are under active evaluation. Subunit formulations, often VP2 combined with VP5 and/or NS1/NS2 virus-like particles (VLPs), and viral-vectored constructs demonstrate favorable safety, strong humoral and cellular responses, inherent or engineered DIVA compatibility, and potential for rapid updating against emergent serotypes. This review synthesizes recent bluetongue activity across the Mediterranean Basin and provides a critical assessment of both existing and emerging vaccine strategies, with a focus on recommending next-generation platforms that emphasize DIVA-compliant, multiserotype, and adaptable vaccination approaches, supported by integrated surveillance and vector control in the region. Full article

Epizootic haemorrhagic disease virus serotype 8 (EHDV-8) emerged in southern Europe in 2022–2023, but clinical and pathological characterization in free-ranging wildlife remains limited. This study investigated EHDV-8-associated morbidity and mortality in wild ruminants in a 2023 outbreak in Sierras de Cazorla, Segura y Las Villas Natural Park (Jaén, Andalusia, Spain). Moribund animals demonstrated a consistent acute neuro-respiratory syndrome characterized by weakness, ataxia, nystagmus and severe dyspnoea with frothy oral discharge. On the carcasses of 39 red deer, two fallow deer, and one mouflon, necropsy was performed and subsequently histopathology and a real-time polymerase chain reaction (RT-PCR) on the collected samples. Gross lesions included marked pulmonary oedema, tracheal foam and widespread congestion, while histopathology revealed lymphoid depletion, pulmonary haemorrhage, vascular injury and renal tubular necrosis. All animals tested positive for EHDV-8 with low RT-qPCR cycle threshold values, indicating high viral loads. This series provides the first confirmed clinical, pathological, and molecular evidence of EHDV-8 infection in fallow deer and mouflon in Europe. The observations demonstrate that EHDV-8 causes a peracute systemic haemorrhagic disease in susceptible wild ruminants and underline the importance of integrated wildlife surveillance and timely diagnostic sampling during peak vector activity. Full article

(1) Background: As an innovative drug derived from botulinum neurotoxin serotype E, TrenibotulinumtoxinE^® demonstrates a rapid onset and shorter effect. Due to concerns regarding specificity, test throughput, and animal welfare, a new cell-based potency assay (CBPA) method was developed for BoNT/E drug substance and drug product; independent evaluation of this new CBPA was required. (2) Methods: The CBPA for BoNT/E is a quantitative assay that measures the accumulated cleaved SNAP25₁₈₀ in human neuroblastoma cells. It involves sequential culturing, differentiation of cells, and then treatment with drug products. Data were analyzed using a quadratic parallel model via statistical software. Linearity was determined using five effective concentration levels. Key assay parameters including accuracy, linearity, repeatability, intermediate precision and range were evaluated. (3) Results: The overall assay’s accuracy was 98%, and the intermediate precision was 6.3%. The coefficient of determination (R²) and slope were determined as 0.963 and 0.942, respectively. The root mean squared error (RMSE) was 0.057, and the intercept was 0.032 for the combined data. The repeatability was 2.4%, which is well within the acceptance criterion of ≤8%. (4) Conclusions: The evaluation was carried out within a single laboratory under controlled conditions; the new CBPA meets all acceptance criteria and can be used for BoNT/E potency determination. Full article

Bluetongue (BT) is an arthropod-borne viral disease primarily affecting domestic and wild ruminants. In recent years, several BTV serotypes and genotypes have been detected in Israel almost annually, raising questions about their origin and routes of introduction. Some BTV serotypes closely related to those first identified in Israel, including BTV-3, BTV-8, and BTV-12, were subsequently reported in Europe after a delay of several years. In this study, we sequenced the complete genomes of one representative strain of all newly identified Israeli BTV genotypes/serotypes—BTV-1, -4, -5, -8, and -11—first detected between 2021 and 2023. Additionally, complete sequences of enzootic Israeli BTV (2015) and eleven BTV-3 strains (2019–2023), with two representative strains for every year of isolation, except 2021 (three strains), were analyzed using phylogenetic, BLAST, and pairwise identity approaches. Genetic analyses revealed that recently identified Israeli and European BTV strains share common African ancestors, with some genomic “incursions” from Mayotte Island or the Arabian Peninsula. These incursions appeared more frequently in Israeli than in European strains. Nevertheless, nucleotide sequence differences of at least 2–3% across all genes indicate several years of independent evolution. The observed divergence suggests that no direct transmission of BTV occurred between Israel and Europe during the past decade. Full article

In this study we employed nanopore whole genome sequencing to analyze the resistance genes, genomic islands and prophage DNA in two multidrug resistant E. rhusiopathiae strains, i.e., 670 and 147, isolated from domestic geese. MLST profiles and core-genome phylogeny were determined to assess strain relatedness. In strain 670 (serotype 8, ST 113), a novel 53 kb prophage φEr670 carrying the lnuB and lsaE resistance genes was identified. Regions highly homologous to the φEr670 prophage were detected in 36 of 586 (6.14%) publicly available E. rhusiopathiae genomes, as well as in some other Gram-positive bacteria, and usually contained resistance genes. E. rhusiopathiae strain 147 (serotype 5, ST 243) was found to contain a composite 98 kb genomic island (GI_Er147) carrying the ant(6)-Ia and spw genes, as well as gene encoding a putative lincosamide nucleotidyltransferase designated lnu(J) and a vat family gene encoding a putative streptogramin A O-acetyltransferase. The lnu(J) gene exhibited 83.6% homology to the lnu(D) gene, and lnu(J)-positive E. rhusiopathiae strains displayed intermediate susceptibility to lincomycin. Vat-positive strain 147 and vat-negative E. rhusiopathiae strains showed similar susceptibility to quinupristin/dalfopristin. The presence of the Tn916 transposon carrying the tetM gene was confirmed in the genomes of both E. rhusiopathiae strains; in strain 147, however, Tn916 was located within ICEEr1012. Based on analyses of additional E. rhusiopathiae genomes, the integration sites of Tn916, ICEEr1012, and GI_Er147 were identified as genomic “hot spots,” contributing to the genome plasticity of E. rhusiopathiae. Prophage φEr670 and GI_Er147 as well as the Tn916 transposon and ICEEr1012 are most likely responsible for the dissemination of resistance genes in E. rhusiopathiae. Prophages highly homologous to φEr670 act as carriers of resistance genes in various Gram-positive bacteria. However, the transferability of the identified genetic elements and the functional role of the lnu(J) gene require further investigation. This study provides new insights into the diversity of MGEs in E. rhusiopathiae and advances understanding of the genomic mechanisms driving antimicrobial resistance in Gram-positive bacteria. Full article

Background: Adeno-associated viruses (AAVs) are widely used vectors for in vivo gene therapy, but their standard storage at −80 °C limits deployment in regions lacking ultracold infrastructure. Strategies enabling stable AAV storage at higher temperatures are needed to support global distribution. Methods: Nine AAV serotypes were lyophilized in simple sucrose-based buffers. Post-lyophilization vector integrity was assessed by measuring in vitro transduction efficiency using a luciferase reporter in cell-based assays. Stability of selected serotypes (AAV2.5 and AAV6) was further evaluated over 8 weeks under varying storage temperatures. Results: Lyophilization in sucrose preserved transduction activity for all tested serotypes (AAV1, AAV2, AAV2.5, AAV3, AAV4, AAV5, AAV6, AAV8, AAV9, and AAVrh10). Notably, AAV2, AAV2.5, and AAV6 exhibited 3- to 6-fold increases in transduction, an effect attributable to the sucrose excipient rather than the lyophilization process itself. Long-term stability of lyophilized vectors varied by serotype, temperature, and vial-seal integrity. AAV6 retained full activity for at least 8 weeks when stored at 4 °C or −20 °C. Conclusions: AAV vectors can be effectively lyophilized in simple sucrose solutions, enabling storage at standard −20 °C freezer temperatures while maintaining functional activity. Optimization of lyophilization buffers and excipients may further extend AAV stability at higher temperatures, improving feasibility for global gene therapy deployment. Full article

Epizootic hemorrhagic disease (EHD) is an important livestock disease caused by Epizootic hemorrhagic disease virus (EHDV). The recent incursion and wide distribution of EHDV in Europe have increased the need for effective vaccine candidates. Background/Objectives: The VP2 protein of EHDV forms the outer capsid layer of the virion and is essential for viral assembly and host cell entry. Owing to its antigenic properties, VP2 represents a major target for vaccine development. However, the recombinant production of VP2 is limited by low stability and poor yields, representing a significant barrier for the generation of safe and effective subunit vaccines. Methods: To overcome these limitations, the VP2 protein from EHDV serotype 8 (EHDV-8) was rationally engineered with targeted modifications at both the amino and carboxyl termini of its coding sequence. Recombinant expression was performed using a baculovirus vector-mediated system in Trichoplusia ni pupae (CrisBio^® technology), employed as living biofactories. Results: The engineering of VP2 resulted in up to a tenfold increase in protein yields compared with the wild-type sequence, while maintaining the trimeric structural integrity of the recombinant protein. Both wild-type and engineered VP2 protein variants were formulated and used to immunize IFNAR(−/−) mice, a model susceptible to EHDV infection. Both engineered and wild-type VP2 formulations elicited comparable neutralizing antibody responses in vaccinated animals. Furthermore, immunization with either formulation conferred full protection against lethal EHDV-8 challenge. Conclusions: In this work, we demonstrated that the rational engineering of the VP2 protein significantly improved recombinant expression yields in a baculovirus-based system without compromising structural integrity or immunogenicity. These findings additionally demonstrate the feasibility of producing high-quality VP2 antigens in T. ni pupae using CrisBio^® technology and support their potential application in the development of subunit vaccines against EHDV. Full article

This study assessed the epidemiological and microbiological invasive pneumococcal disease (IPD) changes that occurred before and after the emergence of COVID-19 in Italy. All IPD cases reported through the nationwide surveillance system during 2018–2023 were included. IPD incidence and serotype distributions were analyzed by age group. IPD incidence in 2020–2021 declined in all age groups compared with 2018–2019, especially in children less than 2 years of age and elderly people aged > 64 years. A resurgence of IPD cases was observed from late 2022 onwards, with values in children exceeding those seen before the pandemic. The post COVID-19 increase in children was mainly driven by some PCV13 serotypes, such as 3, 19A, and 19F, but also non-vaccine serotypes, including 10A, 8, and 24F, while in the elderly population, a predominance of serotypes 3 and 8 was observed. In conclusion, a steep drop in IPD incidence was observed during the peak of the COVID-19 pandemic, followed by a subsequent upsurge of cases, especially in children. Continuous national surveillance is necessary to monitor the dynamics and evolution of IPD and the impact of new higher-valency vaccines in Italy over the next few years. Full article